Randomized Trialhigh evidence
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
The New England journal of medicine·April 13, 2023·PMID 36876740
Why it mattersStatin intolerance limits lipid-lowering options in high-risk patients. This trial provides robust evidence that bempedoic acid reduces cardiovascular events in this population, offering an effective non-statin alternative.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled